Content about Joseph Papa

May 8, 2013

Perrigo: $10 billion in Rx sales may switch OTC through 2018

There is as much as $10 billion in branded pharmaceutical sales that could make the switch from prescription-only to over-the counter in the next five years, suggested Joseph Papa, Perrigo chairman, CEO and president, to analysts on Tuesday.

ALLEGAN, Mich. — There is as much as $10 billion in branded pharmaceutical sales that could make the switch from prescription-only to over-the counter in the next five years, suggested Joseph Papa, Perrigo chairman, CEO and president, to analysts on Tuesday. And as much as $5 billion in the next three years.

March 18, 2013

Perrigo launches store-brand guaifenesin 600-mg extended-release tablets

Perrigo announced that it has begun shipments of guaifenesin 600-mg extended-release tablets. It's the first product that is generically equivalent to Reckitt Benckiser's Mucinex 600-mg extended-release tablets.

ALLEGAN, Mich. — Perrigo on Monday announced that it has begun shipments of guaifenesin 600-mg extended-release tablets. It's the first product that is generically equivalent to Reckitt Benckiser's Mucinex 600-mg extended-release tablets.

February 1, 2013

Perrigo acquires Velcera pet care company

Leading private-label supplier Perrigo has acquired pet health company Velcera for $160 million.

NEW YORK — Leading private-label supplier Perrigo has acquired pet health company Velcera for $160 million.

The deal follows last fall’s acquisition of Sergeants and signals Perrigo’s intent to accelerate growth in areas beyond its traditional businesses of consumer health care, nutrition products and prescriptions. Velcera is a pet health company best known for its PetArmor brand of flea and tick products that are widely available at retailers nationwide, much to the chagrin of veterinarians. PetArmor had sales of $60 million last year.

January 22, 2013

Perrigo launches private label equivalent to Nicorette mini lozenge

Perrigo announced that it has begun shipments of over-the-counter nicotine polacrilex mini lozenge USP, 2 mg (mint flavor) and 4 mg (mint flavor), comparable to GlaxoSmithKline's Nicorette mini lozenge.

ALLEGAN, Mich. — Perrigo on Tuesday announced that it has begun shipments of over-the-counter nicotine polacrilex mini lozenge USP, 2 mg (mint flavor) and 4 mg (mint flavor), comparable to GlaxoSmithKline's Nicorette mini lozenge.

"This launch strengthens Perrigo's leading store brand position in smoking cessation products, which also includes coated and uncoated flavored gums and regular size lozenges," stated Joseph Papa, Perrigo's chairman, president and CEO.

November 8, 2012

Perrigo chief: Store brands big driver behind OTC growth, prepping launch of Mucinex equivalent

Business for OTC store brands is expected to boom in the coming year, Perrigo chairman and CEO Joseph Papa told analysts discussing the private-label manufacturer's first quarter results during a conference call Wednesday, even as the growth rate across the entire OTC category slows.

ALLEGAN. Mich. — Business for OTC store brands is expected to boom in the coming year, Perrigo chairman and CEO Joseph Papa told analysts discussing the private-label manufacturer's first-quarter results during a conference call Wednesday, even as the growth rate across the entire OTC category slows. "What we are seeing though, is the continued acceleration of store brand as being the reason why we're seeing the growth in our OTC category. For us to have a 9.4% growth in our OTC category, we think is a strong indication," Papa said.

October 10, 2012

Perrigo launches store-brand nicotine mini lozenges

Perrigo on Wednesday announced that it has received approval from the Food and Drug Administration for its abbreviated new drug applications to market over-the-counter nicotine polacrilex mini lozenge USP in both 2-mg and 4-mg strengths.

ALLEGAN, Mich. — Perrigo on Wednesday announced that it has received approval from the Food and Drug Administration for its abbreviated new drug applications to market over-the-counter nicotine polacrilex mini lozenge USP in both 2-mg and 4-mg strengths.

The mint-flavored mini lozenge is comparable with GlaxoSmithKline's Nicorette Mini Lozenge and is indicated to reduce withdrawal symptoms, including nicotine craving, associated with quitting smoking.

September 13, 2012

Sergeant's Pet Care gets Perrigo's attention

An expanded offering of private-label pet care products will come soon to retailers' shelves, following the acquisition of Sergeant's Pet Care Products by Perrigo, the leading global provider of store-brand health and personal care items.

ALLEGAN, Mich. — An expanded offering of private-label pet care products will come soon to retailers' shelves, following the acquisition of Sergeant's Pet Care Products by Perrigo, the leading global provider of store-brand health and personal care items.

Perrigo said it signed a definitive agreement to acquire substantially all of the assets of Sergeant's, a privately held Omaha-based company, for $285 million in an all cash deal that enables Perrigo to enter the $8 billion pet care market.

February 17, 2012

Switching things up

Clarinex (desloratadine), the next-generation prescription allergy remedy to the second-generation Claritin, is 1-of-3 blockbuster prescription medicines that may make the crossover from prescription-only to over-the-counter in the near future. If so, the medicine may take the podium as one of the four best-selling allergy brands — Zyrtec and Claritin currently top that list, with Allegra, launched last year, beating out all other cough-cold and allergy tablet brands with more than $220 million in sales through December. 

June 30, 2011

Perrigo's acquisition of Paddock Labs put on hold

Perrigo on Wednesday announced that its closing date to complete the acquisition of Paddock Labs — a generic pharmaceutical and specialty over-the-counter products manufacturer — has been delayed by an extended Federal Trade Commission review.

ALLEGAN, Mich. — Perrigo on Wednesday announced that its closing date to complete the acquisition of Paddock Labs — a generic pharmaceutical and specialty over-the-counter products manufacturer — has been delayed by an extended Federal Trade Commission review.